RxDoctor Payments Data

Sapan Patel, MD

Critical Care Medicine · Austin, TXNPI 1295075661

Payments from drug & device makers

$5,091in general payments, 2019–2025

Across 67 payments — averaging $75.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • AstraZeneca$260
  • Boehringer Ingelheim$225
  • GSK$214
  • Mallinckrodt Enterprises LLC$125
  • United Therapeutics Corporation$117
  • plus $455 from 11 others

What the payments were for

  • Travel & lodging$48810%
  • Food & beverage$1,60331%
  • Education$3,00059%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,091 in reported general payments places this provider in the 80th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$130,708
Medicare patients
407
Services billed
1,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter248$263,505
OfevNintedanib Esylate20$247,699
Breztri AerosphereBudesonide/Glycopyr/Formoterol57$75,782
Spiriva RespimatTiotropium Bromide25$28,046
Breo ElliptaFluticasone/Vilanterol49$27,441
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$16,836
Albuterol Sulfate HfaAlbuterol Sulfate257$11,195
SymbicortBudesonide/Formoterol Fumarate31$10,998
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$6,488
Arnuity ElliptaFluticasone Furoate18$6,304
Ventolin HfaAlbuterol Sulfate21$1,977
Montelukast Sodium175$1,568
Ipratropium Bromide36$1,499
Azithromycin85$1,183
Fluticasone Propionate22$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$214$297,249315 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$225$292,58163 claims
AstraZenecaBreztri Aerosphere, Symbicort$260$86,78188 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →